Literature DB >> 11642515

Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus.

P Horák1, V Scudla, Z Hermanovó, Z Pospisil, L Faltýnek, M Budiková, L Kusá.   

Abstract

The objective of this study was to assess the utility of measurement of thrombomodulin, antinucleosome antibodies, sVCAM-1, sICAM-1, neopterin, fas ligand, IL-10 and sIL-2R in patients with systemic lupus erythematosus (SLE) and to compare them with traditional markers of SLE activity (anti-dsDNA antibodies, C3, C4) and the ECLAM index of disease activity. The measurement was performed over a 6-month period at three consecutive time points after 3 months in each of the 52 patients with SLE. Anti-dsDNA antibodies, thrombomodulin, antinucleosome antibodies, sVCAM-1m sICAM-1, neopterin, fas ligand, IL-10 and sIL-2R were tested by ELISA technique, while C3, C4 components of complement were tested by nephelometry. Fas ligand and IL-10 did not correlate with the ECLAM index. The rest of the markers showed significant correlation with the disease activity index. Thrombomodulin and anti-dsDNA antibodies reflect in the best way the changing trend in disease activity. Antinucleosome antibodies seem to be a promising marker useful in early diagnosis. Soluble VCAM-1, sICAM-1, neopterin and sIL-2R are interesting molecules with a role in disease pathogenesis, but their practical utility is limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642515     DOI: 10.1007/s100670170023

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

Review 1.  Biomarkers in systemic lupus erythematosus.

Authors:  Gabor G Illei; Peter E Lipsky
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

2.  Evaluation of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Discriminating between Active and Non-Active Systemic Lupus Erythematosus.

Authors:  Hasni Mahayidin; Nurul Khaiza Yahya; Wan Syamimee Wan Ghazali; Asmahan Mohd Ismail; Wan Zuraida Wan Ab Hamid
Journal:  Malays J Med Sci       Date:  2016-05

3.  The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value.

Authors:  Hana Ciferská; Pavel Horák; Zuzana Hermanová; Marta Ordeltová; Josef Zadrazil; Tomás Tichý; Vlastimil Scudla
Journal:  Clin Rheumatol       Date:  2006-11-14       Impact factor: 2.980

Review 4.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

5.  Utility of serum ferritin and soluble interleukin-2 receptor as markers of disease activity in childhood systemic lupus erythematosus.

Authors:  Nora Almutairi; Alwaleed Aljaser; Abdulaziz Almutairi; Manal Alshaikh; Abdelmoneim Eldali; Sulaiman M Al-Mayouf
Journal:  Int J Pediatr Adolesc Med       Date:  2019-07-17

6.  Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus.

Authors:  M Tikly; T Gould; A A Wadee; E van der Westhuizen; B B N Mokgethwa
Journal:  Clin Rheumatol       Date:  2007-05-22       Impact factor: 2.980

7.  Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus.

Authors:  Syh-Jae Lin; Ji-Yih Chen; Ming-Ling Kuo; Hsiu-Shan Hsiao; Pei-Tzu Lee; Jing-Long Huang
Journal:  Mediators Inflamm       Date:  2016-10-26       Impact factor: 4.711

8.  Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1.

Authors:  Myles J Lewis; Simon Vyse; Adrian M Shields; Lu Zou; Munther Khamashta; Patrick A Gordon; Costantino Pitzalis; Timothy J Vyse; David P D'Cruz
Journal:  Arthritis Res Ther       Date:  2016-01-08       Impact factor: 5.156

9.  Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.

Authors:  Fabien B Vincent; Rangi Kandane-Rathnayake; Rachel Koelmeyer; James Harris; Alberta Y Hoi; Fabienne Mackay; Eric F Morand
Journal:  Lupus Sci Med       Date:  2020-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.